Lenvatinib plus anti-PD-1 antibodies as conversion therapy for patients with unresectable intermediate-advanced hepatocellular carcinoma: a single-arm, phase II trial

2023113 citationsJournal Articlegold Open Access

Authors

Chinese Clinical Trial Registry, ChiCTR1900023914.

Good health and well-being

Published in: Journal for ImmunoTherapy of Cancer

Volume 11, Issue 9, pp. e007366-e007366

Field-Weighted Citation Impact: 23.05